Obesity News

GLP-1 receptor agonists come with known adverse events — some common and some rare — but recent reports by the public of alopecia and suicidal ideation have the FDA investigating.

An online obesity treatment and maintenance program resulted in significant weight loss among primary care patients, according to findings from a randomized study published in JAMA Internal Medicine.

Along with type 2 diabetes, dyslipidemia and thrombosis, the cardiometabolic diseases of obesity, hypertension and heart disease form a complex triad that poses significant risks to the health of individuals.

People living in extreme poverty had a higher prevalence of heart disease risk factors such as hypertension, diabetes, smoking, obesity and dyslipidemia than previously thought, according to an analysis of people from 78 countries.

Adults with obesity who underwent bariatric surgery had improvements in multiple cardiometabolic measures after surgery, according to findings published in the Journal of the Endocrine Society.

Bariatric surgery will continue to be a therapeutic option for obesity and early diabetes in the future and may be used in combination with newer medications, according to a speaker.

Novo Nordisk and the FDA announced approval of a new indication for semaglutide 2.4 mg for reduction of risk for major adverse cardiovascular events in adults with overweight or obesity and established CVD.

A slew of new medications currently in development may allow health care providers to go beyond glycemic management in the treatment of type 2 diabetes, according to a speaker.

Adults with a higher BMI and waist-to-hip ratio may be more likely to report worse depression, according to study findings published in PLOS ONE.

Men who had a lower birth weight followed by overweight during young adulthood have a greatly increased risk for developing type 2 diabetes vs. those with normal weight at those times, according to study results published in Diabetologia.